Overview
CGEN market data
Price History
CGEN price chart
Valuation & Profitability
- P/E (TTM)
- 6.54 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.38 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.74 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -420.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.30 – $3.24 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $227.9M · P/B 1.39 · P/S 7.53.
Company News
Compugen Q2 EPS $(0.07), Inline, Sales $2.602M Beat $1.606M EstimateBenzinga · Aug 3, 2026, 11:01 AM
Compugen Presents Trial-In-Progress Poster On MAIA-Ovarian Adaptive Platform Trial Of COM701, Potential Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026Benzinga · Jun 18, 2026, 11:15 AM
Compugen To Present Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701, Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026Benzinga · Jun 11, 2026, 11:14 AM
Compugen Q1 2026 Earnings Call: Complete TranscriptBenzinga · Jun 1, 2026, 1:04 PM
Leerink Partners Maintains Outperform on Compugen, Lowers Price Target to $5Benzinga · May 21, 2026, 2:45 PM
Earnings Scheduled For May 18, 2026Benzinga · May 18, 2026, 11:15 AM
Compugen Q1 EPS $(0.08) Misses $(0.07) Estimate, Sales $2.176M Beat $2.095M EstimateBenzinga · May 18, 2026, 11:05 AM